IL214133A - Isolated or cleaned Inganol or its pharmacist salt for skin care - Google Patents

Isolated or cleaned Inganol or its pharmacist salt for skin care

Info

Publication number
IL214133A
IL214133A IL214133A IL21413311A IL214133A IL 214133 A IL214133 A IL 214133A IL 214133 A IL214133 A IL 214133A IL 21413311 A IL21413311 A IL 21413311A IL 214133 A IL214133 A IL 214133A
Authority
IL
Israel
Prior art keywords
purified
isolated
pharmaceutically acceptable
acceptable salt
skin treatment
Prior art date
Application number
IL214133A
Other languages
English (en)
Hebrew (he)
Other versions
IL214133A0 (en
Original Assignee
Leo Lab Ltd
Af 30 April 2003 As
Peplin Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Lab Ltd, Af 30 April 2003 As, Peplin Research Pty Ltd filed Critical Leo Lab Ltd
Publication of IL214133A0 publication Critical patent/IL214133A0/en
Publication of IL214133A publication Critical patent/IL214133A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
IL214133A 2009-02-13 2011-07-18 Isolated or cleaned Inganol or its pharmacist salt for skin care IL214133A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15259909P 2009-02-13 2009-02-13
PCT/AU2010/000152 WO2010091472A1 (en) 2009-02-13 2010-02-12 Skin treatment

Publications (2)

Publication Number Publication Date
IL214133A0 IL214133A0 (en) 2011-08-31
IL214133A true IL214133A (en) 2015-03-31

Family

ID=42561329

Family Applications (1)

Application Number Title Priority Date Filing Date
IL214133A IL214133A (en) 2009-02-13 2011-07-18 Isolated or cleaned Inganol or its pharmacist salt for skin care

Country Status (14)

Country Link
US (1) US10143638B2 (enExample)
EP (1) EP2395993B1 (enExample)
JP (1) JP5638008B2 (enExample)
CN (1) CN102316866A (enExample)
AU (1) AU2010213362B2 (enExample)
CA (1) CA2752389C (enExample)
DK (1) DK2395993T3 (enExample)
ES (1) ES2633755T3 (enExample)
IL (1) IL214133A (enExample)
NZ (1) NZ594184A (enExample)
PL (1) PL2395993T3 (enExample)
PT (1) PT2395993T (enExample)
RU (1) RU2491050C2 (enExample)
WO (1) WO2010091472A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012080466A2 (en) 2010-12-17 2012-06-21 Leo Pharma A/S Ingenols for treating seborrheic keratosis
US9388124B2 (en) 2010-12-22 2016-07-12 Leo Laboratories Limited Ingenol-3-acylates I
AU2011348638B2 (en) * 2010-12-22 2015-05-21 Leo Laboratories Limited 3-acyl-ingenols II
WO2012176015A1 (en) 2011-06-24 2012-12-27 Leo Pharma A/S Methods for treating uv-damaged skin and scc tumors and for removing tattoos with topical ingenol mebutate
EP2790670A1 (en) * 2011-12-12 2014-10-22 Leo Laboratories Limited Gel compositions
WO2013088381A1 (en) * 2011-12-12 2013-06-20 Leo Laboratories Limited Gel compositions
US20150366789A1 (en) * 2013-03-13 2015-12-24 Avon Place, Inc. Glochidium wallichianum extracts and methods of use
US9526714B2 (en) 2014-03-24 2016-12-27 Leo Laboratories Limited Method for treating skin lesions with ingenol mebutate
AU2014100280B4 (en) * 2014-03-24 2015-01-15 Leo Pharma A/S A method of treating skin lesions
US11478409B2 (en) * 2016-05-24 2022-10-25 Natura Cosmeticos S.A. Anti-wrinkle cosmetic composition, composition system and method for cosmetic skin treatment
JP7557192B2 (ja) 2020-08-19 2024-09-27 日本メナード化粧品株式会社 皮膚外用剤及び内用剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08176004A (ja) * 1994-12-21 1996-07-09 Lion Corp 生体老化防止剤及び皮膚用組成物
JPH0987136A (ja) * 1995-07-13 1997-03-31 Shiseido Co Ltd 皮膚外用剤
AUPO864097A0 (en) * 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
AU750624B2 (en) * 1997-08-19 2002-07-25 Leo Laboratories Limited Anti-cancer compounds-I
KR20010057776A (ko) * 1999-12-23 2001-07-05 성재갑 피부미백제
JP4880816B2 (ja) 2000-12-15 2012-02-22 株式会社ヤクルト本社 皮膚老化防止剤
JP3935360B2 (ja) * 2002-01-22 2007-06-20 丸善製薬株式会社 ヒアルロン酸産生促進剤並びに皮膚化粧料及び美容用飲食品
RU2229293C1 (ru) * 2003-04-24 2004-05-27 Хазанов Вениамин Абрамович Лечебно-профилактическое средство для использования в геронтологической практике
US20070224150A1 (en) * 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
JP2007084448A (ja) * 2005-09-20 2007-04-05 Shiseido Co Ltd ヒアルロン酸産生促進剤および皮膚外用剤
BRPI0504797B1 (pt) * 2005-10-27 2020-02-04 Pele Nova Biotecnologia S.A. formulação tópica, método de tratamento cosmético para rejuvenescimento da pele, método de tratamento cosmético e uso de uma formulação
CN101360506A (zh) * 2005-11-25 2009-02-04 派普林研究股份有限公司 创伤愈合的方法
HRP20160181T1 (hr) * 2007-04-30 2016-05-06 Leo Laboratories Limited Tretman virusno induciranih lezija
AU2011241893B2 (en) * 2010-04-16 2014-11-06 Leo Pharma A/S Crystalline ingenol mebutate

Also Published As

Publication number Publication date
EP2395993B1 (en) 2017-06-21
EP2395993A1 (en) 2011-12-21
US20120041064A1 (en) 2012-02-16
CN102316866A (zh) 2012-01-11
RU2011137530A (ru) 2013-03-20
CA2752389C (en) 2017-01-03
IL214133A0 (en) 2011-08-31
NZ594184A (en) 2014-01-31
JP5638008B2 (ja) 2014-12-10
AU2010213362B2 (en) 2015-07-02
ES2633755T3 (es) 2017-09-25
RU2491050C2 (ru) 2013-08-27
AU2010213362A1 (en) 2011-08-04
DK2395993T3 (en) 2017-08-07
PT2395993T (pt) 2017-07-18
EP2395993A4 (en) 2014-09-03
WO2010091472A1 (en) 2010-08-19
PL2395993T3 (pl) 2017-10-31
JP2012517450A (ja) 2012-08-02
CA2752389A1 (en) 2010-08-19
US10143638B2 (en) 2018-12-04

Similar Documents

Publication Publication Date Title
IL214133A (en) Isolated or cleaned Inganol or its pharmacist salt for skin care
HUS000500I2 (hu) Upadacitinib vagy gyógyszerészetileg elfogadható sója
NO2022033I1 (no) Rimegepant or a pharmaceutically acceptable salt thereof
HUS000509I2 (hu) Abemaciklib vagy egy gyógyászatilag elfogadható sója
IL260560B (en) A sulfonyl-amino-pyrimidinyl-amino-benzamide compound for use as a drug in a method for treating cancer in a mammal
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
GB0910003D0 (en) Novel compounds for the treatment of neurodegenerative diseases
IL217768A (en) Coinimod for the treatment of Crohn's disease
PL3064206T3 (pl) Leczenie choroby Huntingtona z zastosowaniem lakwinimodu
IL202014A0 (en) A synergistic pharmaceutical combination for the treatment of cancer
NO2023002I1 (no) Lasmiditan or a pharmaceutically acceptable salt thereof
WO2011014825A3 (en) Antiangiogenic small molecules and methods of use
IL208357A0 (en) Spiro-indole derivatives for the treatment of parasitic diseases
PT2247297T (pt) Tratamento terapêutico para estados pulmonares
PT2539352T (pt) Composições e métodos para tratar doenças cardíacas
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
PT2424870E (pt) Agentes terapêuticos 713
GB201202095D0 (en) Topical medicament for the treatment of psoriasis
IL225755A0 (en) Amido-6 derivatives of epoxymorphinans-a5, 4 for the treatment of pain
ZA201207696B (en) Compound for treatment of respiratory condition or disease
IL193910A (en) Use of petitides to produce a preparation for radioactive injury
SI2595979T1 (sl) Proces za čiščenje farmacevtsko sprejemljivih soli Escitaloprama
GB0906026D0 (en) Therapeutic compounds
ZA201005770B (en) The treatment of damaged skin
GB0715255D0 (en) Thiadiazol-piperazinyl derivatives for the treatment of neurodegenerative diseases

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed